Trial Profile
A phase I clinical trial to assess the safety and immunogenicity of three HIV GTU MultiHIV DNA immunisations administered via the intramuscular, intradermal and transcutaneous routes in healthy male and female volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV DNA vaccine (Primary) ; HIV DNA vaccine (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms CUT HIVAC Spoke 001
- 19 Jul 2015 Status changed from recruiting to completed as per United Kingdom Clinical Research Network record.
- 19 May 2014 New source Identified and integrated (ClinicalTrials.gov record: NCT02075983)
- 27 Feb 2014 According to the ClinicalTrials.gov record, Planned End Date changed from 31 Jul 2014 to 1 Dec 2015.